OCULAR MELANOMA CONFERENCES: FUTURE DATES AND PAST PRESENTATIONS

Links to the videotaped presentations will be posted here when the conference host makes them available online.

Medical Presentations:

•   Session 1: Choroidal Melanoma [a uveal melanoma location]  

— Choroidal Melanoma: Update on Prompt Diagnosis  (keynote presentation)

(Dr. David Ancona-Lezama; 75 minutes)

• Session 2: Radiation Oncology

— Eye Plaque Brachytherapy Treatment [for Uveal Melanoma] in Australia’s Sunshine State 

(Dr. Sarah Li; 15 minutes)

— Stereotactic Radiotherapy (Surgery) for Treatment of Posterior Choroidal Melanoma

(Dr. Claire Phillips; timestamp 14:15; 15 minutes)

— Q&A with above presenters (timestamp 31:15, 10 minutes)    

• Session 3: Latest Australian Ocular Melanoma Research

— Identifying the Roles of BAP1 in Uveal Melanoma 

(Vivian Chua, PhD; 15 minutes)

— Dealing with Uncertainty in the Context of Metastatic

Uveal Melanoma: A Qualitative Study

(Tim Luckett, PhD; timestamp 15:15; 15 minutes)

— Q&A with above presenters (timestamp 31:30; 10 minutes)  

• Session 4: Ocular Melanoma Clinical Trials and Therapies

— Bel-sar: Virus-Like Drug Conjugates as First-Line Treatment of Early-Stage Choroidal Melanoma  [Aura BioSciences presentation]

(Dr. Jill Hopkins; 20 minutes)

— Tebentafusp and Externally Sponsored Research for Ocular Melanoma  [Immunocore and Medison presentation]

(Jennifer Johansen; timestamp 19:15; 15 minutes)

— Uveal Melanoma: Australian Treatment Landscape

(Dr. Mal Ameratunga; timestamp 27:15; 15 minutes)

— Q&A with above presenters (timestamp 44:30; 15 minutes)

— Darovasertib Update for Ocular Melanoma  [Ideaya Biosciences presentation]

(Dennis Chang, PhD; timestamp 1:03:00, 10 minutes)

Links to the videotaped presentations will be posted here when the conference host makes them available online.

Links to the videotaped presentations will be posted here when the conference host makes them available online.

Medical Presentations:

• Morning Video (Part One)

— Uveal Melanoma: Evolving Approach in 2025

(Dr. Carol Shields; timestamp 14:15; 25 minutes)

— Eyes on the Future: What to Expect After Plaque Surgery for Uveal Melanoma

(Dr. Sara Lally; timestamp 39:15; 25 minutes)

— Q&A with above presenters (timestamp 1:03:00; 15 minutes)

— Radiographic Modalities for Follow-Up of Uveal Melanoma 

(Dr. Ashlesha Satish Udare; timestamp 1:19:45; 30 minutes) 

• Morning Video (Part Two)

— Loco-Regional Management of Liver Metastases from Ocular Melanoma

(Dr. Robert Adamo; timestamp 2:45; 35 minutes)

— Standard Care for Metastatic Uveal Melanoma

(Dr. Rino Seedor; timestamp 37:30; 20 minutes)

— Uveal Melanoma in Our Clinical Trials Era

(Dr. Marlana Orloff; timestamp 56:15; 30 minutes)

— Q&A with above presenters (timestamp 1:25:00; 10 minutes)

• Afternoon Video (Part Three)

— Scientific Advances for Uveal Melanoma

(Dr. Andrew Aplin; timestamp 2:15; 25 minutes)

• Afternoon Video (Part Four)

— Ocular Oncology Navigation

(Nurse Navigator Jameson Lynch; timestamp 2:30; 10 minutes)

— Participating in Ocular Melanoma Clinical Trials

(Katherine Senter and Olivia Youman; timestamp 42:00; 20 minutes)

— General Q&A with Dr. Marlana Orloff, Dr. Takami Sato, and Dr. Rino Seedor (timestamp 1:04:30; 25 minutes)

Medical Presentations:

Click on timestamp for start of presentation

5:16  “Ocular Melanoma: Biology, Epidemiology, Diagnosis, and Local Treatment”  (Dr. Andrew W. Stacey; 40 minutes)

47:17  “Proton Therapy for Ocular Melanoma”  (Dr. Jonathan Chen; 40 minutes)

1:28:57  “New Insights into Prognostic Testing for Uveal Melanoma: What You Need to Know”  (Dr. Prithvi Mruthyunjaya; 55 minutes)

2:22:11  “The Immunology of Uveal Melanoma”  (Lucinda Innes, PhD; 15 minutes)

2:35:23   “Promising Systemic Therapeutic Advances for Metastatic Ocular Melanoma”  (Dr. Evan T. Hall; 25 minutes)

3:02:26   “Liver-Directed Immunotherapy for Ocular Melanoma”  (Dr. Shailender Bhatia; 35 minutes)

3:36:58   The Adjuvant Debate: “An Argument for Adjuvant Therapy of Ocular Melanoma"  (Dr. Shailender Bhatia) followed right after by "The Case Against Routine Adjuvant Therapy for Ocular Melanoma"  (Dr. Evan T. Hall) (total time for both presentations: 35 minutes)

All videotaped presentations from this conference

Medical Presentations:

•  Primary Uveal Melanoma (5 sessions; 85 minutes total):

— "Ocular Surveillance — Tumor Control"

 (Dr. Yehonatan Weinberger; begins at time stamp 0:00)

— "Vision Loss After Radiation Treatment (Radiation Retinopathy)"

(Dr. Arun Singh; begins at time stamp 7:15)

— "DNA Testing: Who, When, Why"

(Meghan DeBenedictis, Certified Genetic Counselor; begins at time stamp 20:15)

— "Systemic Surveillance — How?"

(Dr. John Suh; begins at time stamp 34:45)

— "Panel Q & A" (begins at time stamp 1:01:00)

• Metastatic Uveal Melanoma (4 sessions; 90 minutes total):

— "Liver-Directed Therapies"

(Dr. James Isaacs, begins at time stamp 0:00)

— "Immunotherapies and Targeted Therapies"

(Dr. Lucy Boyce Kennedy; begins at time stamp 19:00)

— "Tebentafusp in Practice"

(Dr. Shaheer Khan; begins at time stamp 54:00)

— "Panel Q & A" (begins at time stamp 1:17:00)

• "Preventing Recurrence in Uveal Melanoma: The Role of Adjuvant Therapies"

(Dr. Shaheer Khan; 35 minutes)

• "Uveal Melanoma: Era of Ocular Clinical Trials"

(Dr. Arun Singh; 20 minutes)

• "Uveal Melanoma: Am I Cured Yet?"

(Dr. Arun Singh; 20 minutes)

• "Under the Microscope: Pathology Diagnosis of Ocular Melanoma"

(Dr. Jennifer Brainard; 45 minutes)

All videotaped presentations from this conference

Medical Presentations:

Day 1 Video —

• Current Approaches to the Management of Metastatic Uveal Melanoma 

(Dr. Marcus Butler; 40:35 timestamp start; 45 minutes)

Day 1 includes other videotaped presentations from this symposium

Day 2 Video — 

• Genomic Testing for Uveal Melanoma

(Katherina Alsina, Ph.D.; 3:30 timestamp start; 20 minutes)

Day 2 includes other videotaped presentations from this symposium

Medical Presentations:

Video 1 - Intro and Sessions 1—3:

(Note: Session range on YouTube is incorrectly labeled 1—4)

• 8:00 AM   Welcome

(Dr. Prithvi Mruthyunjaya)

• 8:05 AM   Innovation barriers in ocular oncology

(Dr. Daniel Gombos)

Session 1: What’s in a Picture: Advanced Imaging in Ocular Oncology

• 8:20 AM   Prediction of metastatic risk from fundus photography alone

(Dr. Jared Sokol)

• 8:30 AM   Machine learning analysis of uveal melanoma imaging

(Dr. Michael Heiferman)

• 8:40 AM   AI in ocular oncology for melanocytic lesions

(Dr. Ezekiel Weis)

• 8:45 AM   Ultrawide field OCT in imaging intraocular tumors

(Dr. Alison Skalet)

• 8:50 AM   Trans-palpebral illumination for imaging choroidal tumors

(Dr. Michael Heiferman)

• 9:00 AM   Quantitative high-definition microvessel imaging to distinguish choroidal nevus versus melanoma

(Dr. Lauren Dalvin)

• 9:10 AM   Panel Discussion

(Moderators: Dr. Prithvi Mruthyunjaya and Dr. Jens Killgard)

Session 2: Retinoblastoma 9:30 — 10:30

Session 3: Everyday Problems, New Solutions

• 10:50 AM   How will we use the new COOG2 outcome data?

(Dr. Prithvi Mruthyunjaya)

• 11:00 AM   Iris melanoma: Predictive analysis

(Dr. Arun Singh)

• 11:10 AM   Plaque brachytherapy for conjunctival tumors

(Dr. Hakan Demirci)

• 11:20 AM   Ocular outcomes from systemic therapy for von Hippel-Lindau disease

(Dr. Brian Marr)

• 11:30 AM   Melanoma in situ and squamous cell carcinoma: New potential treatment

(Dr. Randy Christopher Bowen)

• 11:40 AM   Panel Discussion

(Moderators: Dr. Hakan Demirci and Dr. Miguel Materin)

Video 2 - Sessions 4—8:

(Note: Session range on YouTube is incorrectly labeled 5—8)

Session 4: Fluid Is the Fashion (No Longer Tissue Is the Issue)

• 12:00 PM   Proteomics of the tumor mesoenvironment in uveal melanoma

(Dr. Vinit Mahajan)

• 12:10 PM   Aqueous Humor Proteomics for melanoma: A new companion diagnostic

(Dr. Jesse Berry)

• 12:20 PM   The living library for uveal melanoma: Multiomics characterization and utility in drug screening

(Dr. Lauren Dalvin)

• 12:30 PM   Panel Discussion

(Moderators: Dr. Vinit Mahajan and Dr. Jessie Berry)

Session 5: Is Less Really More?: Redirecting Local Treatments in Uveal Melanoma

• 1:45 PM   Ocular radiation dose reduction and vision outcomes

(Dr. Brian Marr)

• 1:55 PM   Dose reduction for radiation therapy in uveal melanoma: Are we ready for a clinical trial?

(Dr. Miguel Materin)

• 2:05 PM   Bel-sar phase 3 and beyond

(Dr. Ivana Kim)

• 2:15 PM   Early biopsy and treatment/observation decision analysis

(Dr. Ezekiel Weis)

• 2:25 PM   Panel Discussion

(Moderators: Dr. Lauren Dalvin and Dr. Arun Singh)

Session 6: Keynote Address

• 2:45 PM   Optimizing prognostication in uveal melanoma

(Dr. Jens Folke Kiilgaard)

• 3:00 PM   Question and Answer Session

Session 7: Progress in Systemic Disease

• 3:05 PM   Current standards in metastatic uveal melanoma

(Dr. Kevin Kim)

• 3:15 PM   Liver directed therapy for metastatic melanoma

(Dr. Sunil Reddy)

• 3:25 PM   Neo-adjuvant therapy for uveal melanoma

(Dr. Pauline Funchain)

• 3:35 PM   Current states of clinical investigation

(Dr. Allison Betof-Warner)

• 3:45 PM   BAP1 tumor predisposition syndrome

(Dr. Colleen Cebulla)

• 3:55 PM   Current status of ctDNA assays for uveal melanoma

(Dr. Ivana Kim)

• 4:05 PM   Panel Discussion

(Moderators: Dr. Allison Betof-Warner and Dr. Ezekiel Weis)

Session 8: Challenging Cases in Ocular Oncology

• 4:35 PM   Panel Discussion: Challenging Cases

Medical Presentations:

• Understanding Clinical Drug Trials: A Doctor’s Perspective for Uveal Melanoma Patients

(Dr. Meredith McKean, Dr. Justin Moser, and Dr. Inderjit Mehmi; 30 minutes)

• Histotripsy and Hepzato: The Future of Liver Cancer Treatment for Uveal Melanoma Metastases

(Dr. Matt Hadfield, Dr. Jason Low, Dr. Vincent Ma, and Dr. Justin Moser; 30 minutes)

• Genetic Metastatic Testing in Uveal Melanoma: Advancements & Challenges

(Dr. Matt Hadfield, Dr. Justin Moser, and Dr. Peaches Ulrich; 40 minutes)

• Understanding Prosthetic Eye Side Effects After Enucleation for Ocular Melanoma

(Dr. Lisa Mihora and Ocularist Starla Allen; 45 minutes)

• "Cancer Detection: The Future of Liquid Biopsies in Uveal Melanoma"

(Dr. Vincent Ma; 45 minutes)

Medical Presentations:

• Post-Radiotherapy Eye Monitoring of Ocular Melanoma Patients: Why It Matters and Managing Complications

(Dr. Guy Negretti; 25 minutes)

• Building the Digital Database & Advancing Uveal Melanoma Research

(Dr. Helen Kalirai; 30 minutes)

• 1) How to Identify an Expert in Uveal Melanoma and 2) The Role of Next Generation Sequencing in Uveal Melanoma

(Professor Paul Nathan; 35 minutes)

• Conjunctival Melanoma and its Precursor Lesions

(Dr. Yamini Krishna; 20 minutes)

• An Update on Clinical Trials for Uveal Melanoma in the UK

(Dr. Heather Shaw; 30 minutes)

• Why Me?, Why is My Treatment and Followup Different Than Other Patients?, and Other Popular Questions

(Dr. Hibba Quhill; 30 minutes)

• Chemosaturation Treatment for Ocular Melanoma Metastatic Disease

(Dr. Pavan Najran; 20 minutes)

All videotaped presentations from this conference

Medical Presentations:

Morning Video (Part One)

• Uveal Melanoma Basic Science Research

(Andrew Aplin, PhD; 14:20 time stamp; 30 minutes)

• Current Management of Uveal Melanoma

(Dr. Sara Lally; 47:00 time stamp; 45 minutes)

Morning Video (Part Two)

• Risk Assessment and Follow-Up of Uveal Melanoma

(Dr. Rino Seedor; 0:00 time stamp; 15 minutes)

• Neo-Adjuvant and Adjuvant Treatment for High-Risk Primary Uveal Melanoma

(Dr. Rino Seedor; 21:00 time stamp; 20 minutes)

• Systemic Treatments for Metastatic Uveal Melanoma

(Dr. Marlana Orloff; 43:00 time stamp; 30 minutes)

• Multidisciplinary Care, Early Diagnosis & Imaging, and the Rationale for Liver-Directed Treatments for Metastatic Uveal Melanoma

(Dr. Robert Adamo; 1:14:00 time stamp; 25 minutes)

• Immunoembolization and Percutaneous Hepatic Perfusion as Treatment for Metastatic Uveal Melanoma

(Dr. David Eschelman; 1:39:00 time stamp; 20 minutes)

• Radioembolization & Chemoembolization of Uveal Melanoma Hepatic Metastases

(Dr. Carin Gonsalves; 2:00:00 time stamp; 25 minutes)

• The Role of Radiation for Metastatic Uveal Melanoma

(Dr. Pramila Rani Anne; 2:24:00 time stamp; 15 minutes)

Afternoon Video (Part Three)

Presentations from non-profit OM patient organizations about their activities and services are posted on EyeMelanoma.org's Organizations webpage, This video does not contain medical presentations.]

Afternoon Video (Part Four)

• Participating in Ocular Melanoma Clinical Trials [the process plus Q&A]

(Melanoma Research Team Nurse Manager Tina Savio, Assistant Director for Research Operations Katherine Senter, and Dr. Takami Sato; 0:00 time stamp; 60 minutes)

Medical Presentations:

Video 1:

• Moving Towards Cure: A New Chapter for Patients with Uveal Melanoma

(Dr. Richard Carvajal; link preset at 3:45 time stamp; 30 minutes)

Video 2:

• Update on Uveal Melanoma Registries

(Prof. Anthony Joshua; link preset at 0:40 time stamp; 15 minutes)

• IDEAYA Biosciences: Darovasertib Clinical Development for Ocular Melanoma

(Dr. Darrin Beaupre; link preset at 30:29 time stamp; 10 minutes)

Video 3:

• Tebentafusp – What You Need to Know as an Ocular Melanoma Patient

(Prof. Anthony Joshua; link preset at 0:00 time stamp; 20 minutes)

• Targeting GNAQ and GNA11 in Uveal Melanoma

(Assoc. Prof. Matteo Carlino; link preset at 18:52 time stamp; 15 minutes)

Video 4:

• Uveal Melanoma Testing: Options, Interpretation, and Access Pathways

(Prof. Svetlana Cherepanoff; link preset at 0:00 time stamp; 15 minutes)

• Circulating Tumour DNA as a Biomarker in Uveal Melanoma

(Dr. Aaron Beasley; link preset at 15:44 time stamp; 10 minutes)

Video 5:

• How We Work Up Uveal Melanoma: An Ophthalmologist’s Perspective for Patients

(Dr. Tim Isaacs; link preset at 0:00 time stamp; 20 minutes)

• Artificial Eyes in Rehabilitation of Ocular Melanoma Patients

(Ocularist Jenny Geelen; link preset at 22:30 time stamp; 20 minutes)

Video 6:

• Advances in Radiation Treatment of Uveal Melanoma — Australia's New South Wales Experience

(Dr. Wenchang Wong; link preset at 14:15 time stamp; 20 minutes)

Video 7:

• FOCUS Clinical Trial (Percutaneous Hepatic Perfusion): The End of the Beginning for Liver Directed Therapy in Metastatic Uveal Melanoma

(Dr. Joseph Sacco; link preset at 0:00 time stamp; 30 minutes) 

All videotaped presentations from this conference

The time stamp info below shows where you will find the specific presentation within the video.

Medical Presentations:

Track 1 – Morning Video

• Ocular Melanoma: Diagnosis, Biopsies, and Proton Irradiation

(Dr. Frances Wu; 1:20:00 time stamp; 20 minutes)

• Plaque Brachytherapy and Gamma Knife for Ocular Melanoma Patients

(Dr. Shilpa Desai; 1:44:00 time stamp; 15 minutes)

• What to Expect After Radiation for Uveal Melanoma

(Dr. Ivana Kim; 1:58:00 time stamp; 40 minutes)

• Ocular Melanoma Surveillance and Adjuvant Treatment

(Dr. Ryan Sullivan; 2:37:00 time stamp; 45 minutes)

Track 1 – Afternoon Video

• Overview of Metastatic Treatment Approaches in Uveal Melanoma

(Dr. Kamaneh Montazeri; 3:00 time stamp; 25 minutes)

• Tebentafusp in Practice for Ocular Melanoma Patients

(Dr. Ryan Sullivan; 30:29 time stamp; 35 minutes)

• Liver-Directed Therapies for Ocular Melanoma Patients

(Dr. Eric Wehrenberg-Klee; 1:06:00 time stamp; 25 minutes)

• Targeted Systemic Therapies for Uveal Melanoma

(Dr. Rizwan Haq; 1:33:00 time stamp; 25 minutes)

• Immunotherapies for Metastatic Uveal Melanoma

(Dr. Elizabeth Buchbinder; 1:59:00 time stamp; 20 minutes)

Track 2 – Morning Video

• Changes in Sexual Health During and After Ocular Melanoma Cancer Treatment

(Cristina Pozo-Kaderman, PhD; 22:00 time stamp; 40 minutes)

Track 2 – Afternoon Video

• Oncology Nutrition Fact Versus Fiction

(Christina Conte, Registered Dietician; 1:22:00 time stamp; 60 minutes)

Conference's Science Sunday Video 

• The Potential for Circulating Biomarkers in Uveal Melanoma

(Dr. Ryan Sullivan; 57:00 time stamp; 35 minutes)

• Liver Metastases in Ocular Melanoma: Some New Research That I Am Excited About

(Dr. Rizwan Haq; 1:35:00 time stamp; 35 minutes)